medigraphic.com
ISSN 1561-3054 (Electronic)

2016, Number 3

<< Back Next >>

Rev Cubana Med Trop 2016; 68 (3)

Antifungal susceptibility of Candida spp. vaginal isolates

Perurena LM, Pérez MY, Fernández ACM, Martínez MG, Illnait ZMT

Language: Spanish
References: 19
Page: 248-254
PDF size: 124.68 Kb.


ABSTRACT

Introduction: vulvovaginitis is one of the main gynecological diseases frequently caused by candidiasis. Candida albicans is considered as the most important etiological agent for the disease; however, recent students have revealed an increased incidence of other species of the genus. Some of them may show particular resistence to usual antimycotic treatments.
Objective: to evaluate the antifungal susceptibility of vaginal isolates from Cuban female patients suspected of vulvovaginal candidiasis in 2015.
Methods: twenty eight Candida genus isolates underwent in vitro susceptibility tests with ATBTM Fungus 3 using several antifungal agents (5 fluorocytosine, anphotericin B, fluconazole, itraconazole and vorixonazole).
Results: all isolates were susceptible to B anphotericin and one C. albicans isolate was reported as resistant to the studied azoles. All the species other thanC. albicans were susceptible to voriconazole (CMI≤ 1mg/L).
Conclusions: the study of susceptibility patterns in Candida isolates from women with vulvovaginitis allow delving into the different ways of approaching the therapeutics of this disease; fluconazole was the treatment of choice. The results show emergence of C. glabrata,C. krusei, C. parapsilosis, C. tropicalis, C. inconspicua and C. lusitaniae as causative agents of vulvovaginal candidiasis.


REFERENCES

  1. Cararach M, Comino R, Davi E, Marimon E, Martínez JC, Palacios S, et al. La vulvovaginitis candidiásica recurrente. Prog Obstet Ginecol. 2013;56(2):108-16.

  2. Mahmoudi RM, Zafarghandi S, Abbasabadi B, Tavallaee M. The epidemiology of Candida species associated with vulvovaginal candidiasis in an Iranian patient population. Eur J Obstet Gynecol Reprod Biol. 2011;155(2):199-203.

  3. Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG. 2015;122:785-94.

  4. Davies S, Johnson E, White D. How to treat persistent vaginal yeast infection due to species other tan Candida albicans. Sex Transm Infect. 2013;89:165-6.

  5. Babic M, Bosn H. Candida albicans and non-albicans species as etiological agent of vaginitis in pregnant and non-pregnant women. J Basic Med Sci. 2010;10(1):89- 97.

  6. Hettiarachchi N, Ashbee HR, Wilson JD. Prevalence and management of nonalbicans vaginal candidiasis. Sex Transm Infect. 2010;86(2):99-100.

  7. Romero R, Nygaard I. CDC updates guidelines for treating sexually transmitted diseases. Am J Obstet Gynecol. 2015;213:117-8.

  8. Manual ATBTM Fungus 3. Francia: BioMérieux SA; 2002.

  9. Wayne PA. Clinical and Laboratory Standards Institute: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. CLSI document M27-A3. CLSI. 2008;28:6-12.

  10. Dolande ME, Vera F, Panizo MM, Macero C, Moreno X, Calvo A, et al. Distribución y sensibilidad a los antifúngicos de aislamientos clínicos de Candida en seis centros de salud del área metropolitana de Caracas, Venezuela. Rev Iberoam Micol. 2008;25:17-21.

  11. Cuenca M. Antifúngicos en el tratamiento de las infecciones sistémicas: importancia del mecanismo de acción, espectro de actividad y resistencias. Rev Esp Quimioter. 2010;23(4):169-76.

  12. Shahid Z, Sobel JD. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis. 2009;64:354-6.

  13. Rambach G, OberhauseHr, Speth C, Lass-Florl C. Susceptibility of Candida species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey. Med Mycol. 2011;49:856-63.

  14. Mathema BE, Cross ED, Park S, Bedell J, Slade B, Williams M, et al. Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Infect Dis. 2011;33:23-7.

  15. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005;43(5):2155-62.

  16. Liu XP, Fan SR, Bai FY, Li J, Liao QP. Antifungal susceptibility and genotypes of Candida albicans strains from patients with vulvovaginal candidiasis. Mycoses. 2009;52:24-8.

  17. Gunther LSA, Martins HPR, Gimenes F, Abreu ALP, Consolaro MEL, Svidzinski TIE. Prevalence of Candida albicans and non- albicans isolates from vaginal secretions: comparative evaluation of colonization, vaginal candidiasis and recurrent vaginal candidiasis in diabetic and non-diabetic women. São Paulo Med J. 2014;132(2):116-20.

  18. Holland J, Young ML, Lee O, Chen CA. Vulvovaginal carriage of yeasts other than Candida albicans. Sex Transm Infect. 2003;79:249-50.

  19. Pappas PG , Kauffman CA , Andes DR , Clancy CJ , Marr KA , Ostrosky-Zeichner L , et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50.




2020     |     www.medigraphic.com